Hvad er oversættelsen af " RISK- FORHOLDET " på engelsk?

• risk ratio

Eksempler på brug af Risk- forholdet på Dansk og deres oversættelser til Engelsk

Samlet konklusion vedrørende benefit/ risk- forholdet.
Overall conclusion on benefit/ risk.

Er af den opfattelse, at benefit/ risk- forholdet for Dynastat ved korttidsbehandling af.
Is of the Opinion that the benefit/ risk balance of Dynastat in the short-term treatment of.

Der er identificeret væsentlige forskelle med hensyn til benefit/ risk- forholdet for produktet.
Significant differences have been identified with regard to the benefit/ risk ratio of the product.

CHMP var betænkelig ved, at benefit/ risk- forholdet for denne indikation ikke kunne fastlægges på passende vis.
The CHMP was concerned that the benefit/ risk ratio of this indication could not be adequately established.

Ansøgeren skulle gennemgå sikkerheden og virkningen af cefuroximaxetil ved ukompliceret gonorré og drage konklusioner om benefit/ risk- forholdet for denne ansøgte indikation.
The applicant had to address the safety and efficacy of cefuroximaxetil in uncomplicated gonorrhoea and to conclude on the risk-benefit balance for this sought indication.

CHMP var af den opfattelse, at benefit/ risk- forholdet for denne indikation er positivt.
The CHMP considered the benefit/ risk ratio of this indication is positive.

Benefit/ risk- forholdet for produktet er stadig gunstigt og er fortsat uændret efter afslutningen af voldgiftsproceduren.
The Benefit/ Risk ratio of the product is still favourable and remains unchanged at the end of the arbitration procedure.

Som følge heraf vurderede komitéen, at benefit/ risk- forholdet for lægemidler indeholdende.
The Committee, as a consequence, considered the benefit/ risk balance of medicinal products.

Det konkluderes, at benefit/ risk- forholdet begunstiger den opfattelse, at nifedipine til kvinder i den fødedygtige alder eller til ammende kvinder ikke bør kontraindiceres.
In conclusion, the benefit/ risk ratio favours the opinion that the use of nifedipine should not be contraindicated for women capable of childbearing or for nursing women.

Der blev udført en samlet evaluering frem til 30. september 2007 af alle hepatiske bivirkninger(alvorlige og ikke- alvorlige) og en samlet vurdering af benefit/ risk- forholdet for moxifloxacin- behandling.
A cumulative review up to 30 September 2007 of all hepatic reactions(serious and non-serious) and an overall assessment of the benefit/ risk ratio of moxifloxacin treatment was performed.

Efter gennemgang af alle fremlagte oplysninger og den faglige drøftelse i Udvalget vurderede CHMP på sit møde i juni 2008, at benefit/ risk- forholdet for Activelle og tilknyttede navne er positivt, at Frankrigs og Tysklands indvendinger ikke skulle stå i vejen for udstedelse af en markedsføringstilladelse, og at produktresuméet, etiketteringen og indlægssedlen i referencemedlemsstaten skulle ændres.
During their June 2008 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Activelle and associated names, that the objections raised by France and Germany should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.

På sit møde i juni 2005 var CHMP på grundlag af de samlede forelagte oplysninger og den faglige drøftelse i udvalget af den opfattelse, at benefit/ risk- forholdet var gunstigt for Lansopon.
During its June 2005 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Lansopon.

På baggrund af alle de forelagte oplysninger og den faglige drøftelse i udvalget var CHMP på sit møde i september 2007 af den opfattelse, at benefit/ risk- forholdet er gunstigt for Bicaluplex og tilknyttede navne, at de indsigelser, der er rejst af Tyskland, ikke bør forhindre udstedelse af en markedsføringstilladelse, og at referencemedlemsstatens produktresumé, etikettering og indlægsseddel bør ændres.
During their September 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Bicaluplex and associated names, that the objections raised by Germany should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.

Risk/ benefit- hensyn På grundlag af den af indehaveren af markedsføringstilladelsen indleverede dokumentation, herunder forslaget om indførelse af et svangerskabsforebyggende program, og udvalgets faglige drøftelser fandt CPMP, at benefit/ risk- forholdet for Roaccutan(og tilknyttede navne) er gunstigt for de godkendte indikationer.
Benefit/ Risk considerations Based on the documentation submitted by the Marketing Authorisation Holders including the proposal for implementation of a pregnancy prevention programme and the scientific discussion within the Committee, the CPMP considered that the benefit/ risk ratio of Roaccutane(and associated names) is positive for the agreed indications.

På sit møde i juli 2007 fandt CHMP på baggrund af alle forelagte oplysninger og den faglige drøftelse i udvalget, at benefit/ risk- forholdet er gunstigt for Fentanyl- ratiopharm 25/ 50/ 75/ 100 µg/ h TTS og tilknyttede navne, at de af Frankrig rejste indvendinger ikke bør forhindre udstedelse af en markedsføringstilladelse, og at referencemedlemsstatens produktresumé, etikettering og indlægsseddel bør ændres.
During their July 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Fentanyl- ratiopharm 25/ 50/ 75/ 100 µg/ h TTS and associated names, that the objections raised by France should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.

På sit møde i april 2005 var CHMP på grundlag af de samlede forelagte oplysninger og den faglige drøftelse i udvalget af den opfattelse, at benefit/ risk- forholdet var gunstigt for Crestor 5 mg eller Crestor 10 mg som startdosis.
During its April 2005 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Crestor 5 mg or Crestor 10 mg as start dose.

På sit møde den 13.- 16. november 2006 var CHMP på grundlag af de forelagte oplysninger og den faglige drøftelse i udvalget af den opfattelse, at benefit/ risk- forholdet for Ciprofloxacin Nycomed og tilknyttede navne er gunstigt, at indsigelserne, der var rejst af Norge og Sverige, ikke bør være til hinder for udstedelsen af en markedsføringstilladelse, og at referencemedlemsstatens produktresumé, etikettering og indlægsseddel bør ændres.
During their 13-16 November 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Ciprofloxacin Nycomed and associated names, that the objections raised by Norway and Sweden should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.

Efter gennemgang af alle fremlagte oplysninger og den faglige drøftelse i udvalget vurderede CHMP på sit møde i juni 2008, at benefit/ risk- forholdet for Rapinyl og tilknyttede navne er positivt, at de indvendinger, som Tyskland, Frankrig, Norge og Det Forenede Kongerige havde rejst, ikke skulle stå i vejen for udstedelse af en markedsføringstilladelse, og at produktresuméet, etiketteringen og indlægssedlen i referencemedlemsstaten skulle ændres.
During their June 2008 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Rapinyl and associated names, that the objections raised by Germany, France, Norway and United Kingdom should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, Labelling and Package Leaflet of the Reference Member State should be amended.

På baggrund af alle de fremlagte oplysninger og den faglige drøftelse i udvalget var CHMP på sit møde i december 2007 af den opfattelse, at benefit/ risk- forholdet er gunstigt for Yasminelle og tilknyttede navne, at de indsigelser, der er rejst af Ungarn, ikke bør forhindre godkendelse af den ændring, hvorom der er indgivet ansøgning, og at referencemedlemsstatens produktresumé, etikettering og indlægsseddel skulle udgøre den endelige udgave, som var opnået under koordineringsgruppens procedure.
During their December 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Yasminelle and associated names, that the objections raised by Hungary should not prevent the approval of the variation applied for and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be the final versions achieved during the Coordination group procedure.